Equities

E-Therapeutics PLC

ETX:LSE

E-Therapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)9.80
  • Today's Change0.20 / 2.08%
  • Shares traded2.33m
  • 1 Year change-27.27%
  • Beta-0.2280
Data delayed at least 20 minutes, as of Apr 26 2024 16:35 BST.
More ▼

Profile data is unavailable for this security.

About the company

e-Therapeutics Plc is a drug discovery platform company. It is engaged in developing a computational approach to drug discovery, leveraging network biology to capture and interrogate human disease complexity. Its biology-led silico laboratory enables hypothesis generation, phenotypic screening and the identification and prioritization of novel therapeutic targets. It has developed a proprietary GalNAc-siRNA platform technology for specific silencing of gene expression in the liver. Its computational platform includes HepNet, a hepatocyte-specific, computational biology platform that enables identification of target genes to unlock differentiated therapeutic development at scale. Its GalOmic platform is its proprietary ribonucleic acid (RNA) Interference (RNAi) chemistry platform. In combination with HepNet, it offers end-to-end capabilities for rapid identification of novel disease-associated genes and drug candidate development of therapies with disease-modifying potential.

  • Revenue in GBP (TTM)475.00k
  • Net income in GBP-8.27m
  • Incorporated2001
  • Employees38.00
  • Location
    E-Therapeutics PLCFloor 44 Kingdom Street, Paddington CentralLONDON W2 6BDUnited KingdomGBR
  • Phone+44 20 4551 8888Fax+44 19 9388 0207
  • Websitehttps://www.etherapeutics.co.uk/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Science in Sport PLC65.93m-7.07m28.71m158.0028.71m158.00
CRUSHMETRIC Group Ltd398.65k-880.15k30.10m20.0030.10m20.00
Redx Pharma PLC4.20m-33.16m35.01m101.0035.01m101.00
Arecor Therapeutics PLC3.38m-9.42m41.81m51.0041.81m51.00
Venture Life Group PLC51.41m921.00k52.50m165.0052.50m165.00
e-Therapeutics plc475.00k-8.27m57.26m38.0057.26m38.00
Poolbeg Pharma PLC0.00-4.89m59.00m12.0059.00m12.00
Celadon Pharmaceuticals PLC20.74k-8.06m65.81m--65.81m--
Eco Animal Health Group Plc88.46m-1.62m72.83m228.0072.83m228.00
Data as of Apr 26 2024. Currency figures normalised to E-Therapeutics PLC's reporting currency: UK Pound GBX

Institutional shareholders

12.25%Per cent of shares held by top holders
HolderShares% Held
Bank J. Safra Sarasin AG (Investment Management)as of 01 Apr 202425.30m4.33%
Schroder Investment Management Ltd.as of 01 Apr 202413.90m2.38%
Investec Wealth & Investment Ltd.as of 01 Apr 20248.20m1.40%
Fidelity Investments Canada ULCas of 01 Apr 20245.86m1.00%
IG Markets Ltd.as of 01 Apr 20245.01m0.86%
Cantor Fitzgerald Europeas of 01 Apr 20244.57m0.78%
Hargreaves Lansdown Asset Management Ltd.as of 01 Apr 20242.92m0.50%
Coutts & Co.as of 01 Apr 20242.76m0.47%
Rathbones Investment Management Ltd.as of 01 Apr 20241.86m0.32%
KW Investment Management Ltd.as of 01 Apr 20241.22m0.21%
More ▼
Data from 31 Dec 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.